FOS and hypercalcemia disease: Lupeol is reported to inhibit osteoclast differentiation and bone resorption through RANK, nuclear factor kappa-B (NF-kB), nuclear factor of activated T-cells (NFATC) and c-Fos (a proto-oncogene) in-vitro and in-vivo in an animal model of hypercalcemia mediated bone porosity [62].